Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$5.83
>-$0.01(-0.49%)
At close: 4:00 PM EST
$5.83
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$3.76 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$44.69M
Enterprise Value$12.98M
Total Cash (Recent Filing)$31.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 17, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding8,611,361
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.08K
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$23.00Price Target Upside294.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers fixed obligations and interest risk for a clinical-stage biotech that lacks product cash flows. Over the next 2-6 months this preserves financing optionality and reduces near-term insolvency pressure, allowing management to prioritize development milestones over debt servicing.
Resolved Patent DisputesSettling Endoxifen IP litigation and preserving key patents reduces legal overhang and strengthens Atossa’s ability to develop and commercialize Z-endoxifen base. This durable reduction in IP uncertainty supports long-term R&D planning, partner discussions, and potential exclusivity in targeted oncology niches.
Governance And Capital-Structure FlexibilityShareholder approvals delivered board continuity, auditor ratification, and authorization for a reverse split. This sustains governance stability and gives management a structural tool to maintain listing eligibility and manage capital structure, improving strategic flexibility for raising institutional capital if needed.
Bears Say
No Revenue And Widening LossesPersistent zero revenue combined with materially widening net losses is a core structural weakness for a clinical-stage firm. Without product cash flows, the company remains entirely dependent on external financing to fund operations and trials, increasing dilution and execution risk over the medium term.
Eroding Equity BaseA sharply declining equity base signals cumulative losses have materially depleted shareholder capital. Over months this weakens the company’s financial cushion, reduces borrowing collateral, and raises the probability management must seek dilutive capital or strategic transactions to sustain development programs.
Negative And Accelerating Cash BurnConsistently negative operating and free cash flows with acceleration in burn create a structural funding gap. This persistent cash outflow pattern increases reliance on financing rounds, constrains long-term planning, and elevates risk of trial delays or program prioritization if new capital is delayed or more expensive.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $3.76 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $44.69M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 79 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 08, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.99 by -$0.12.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -1.08.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 8,611,361 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.99. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (294.51% Upside)
$23.00 (294.51% Upside)
Hedge Fund Trend
Decreased
By 14.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.34%
12-Months-Change
Fundamentals
Return on Equity
-84.91%
Trailing 12-Months
Asset Growth
-46.37%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$23.00
▲(294.51% Upside)
Technical Analysis
Ownership Overview
2.51% Insiders
29.51% Mutual Funds
<0.01% Other Institutional Investors
63.97% Public Companies and
Individual Investors